Menu
Search
|

Menu

Close
X

Ironwood Pharmaceuticals Inc IRWD.OQ (NASDAQ Stock Exchange Global Select Market)

15.36 USD
-0.14 (-0.90%)
As of Feb 16
chart
Previous Close 15.50
Open 15.41
Volume 469,924
3m Avg Volume 427,511
Today’s High 15.91
Today’s Low 15.19
52 Week High 19.94
52 Week Low 13.00
Shares Outstanding (mil) 149.76
Market Capitalization (mil) 2,300.25
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.75 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY17
298
FY16
274
FY15
150
EPS (USD)
FY17
-0.788
FY16
-0.564
FY15
-1.004
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
7.71
8.57
Price to Book (MRQ)
vs sector
233.48
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
4,065.95
15.12
LT Debt to Equity (MRQ)
vs sector
4,022.04
11.85
Return on Investment (TTM)
vs sector
-20.19
13.54
Return on Equity (TTM)
vs sector
-305.46
14.80

EXECUTIVE LEADERSHIP

Terrance McGuire
Non-Executive Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Peter Hecht
Chief Executive Officer, Director, Since 1998
Salary: $100,000.00
Bonus: --
Gina Consylman
Chief Financial Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
William Huyett
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Mark Currie
Senior Vice President, Chief Scientific Officer, President - Research and Development, Since 2002
Salary: $454,000.00
Bonus: $301,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

301 Binney St
CAMBRIDGE   MA   02142-1030

Phone: +1617.6217722

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

SPONSORED STORIES